News & Updates

Higher refined grains intake ups risk of death, major CV events

08 Feb 2021 by

People who regularly consume refined grains are at greater risk of death and major cardiovascular (CV) events, claims a study. On the other hand, eating whole grains or white rice shows no association with these clinical outcomes.

Higher refined grains intake ups risk of death, major CV events

08 Feb 2021

No need for warfarin after isolated mitral valve repair, says study

07 Feb 2021

Warfarin does not seem to provide additional benefit or risks following isolated mitral valve repair (MVr), reports a recent meta-analysis.

No need for warfarin after isolated mitral valve repair, says study

07 Feb 2021

Does gender-affirming hormone therapy affect BP of transgenders?

06 Feb 2021

The impact of gender-affirming hormone therapy (GHT) on blood pressure (BP) in transgender individuals remains unclear, as shown by data from a systematic review.

Does gender-affirming hormone therapy affect BP of transgenders?

06 Feb 2021

Bayer pharma applies breakthrough innovations to manage difficult-to-treat conditions

05 Feb 2021 by

Bayer reveals major transformation in its pharmaceutical business with the use of breakthrough innovations aimed at helping patients with difficult-to-treat conditions.

Bayer pharma applies breakthrough innovations to manage difficult-to-treat conditions

05 Feb 2021

Heart failure post-MI more frequent in women than men

04 Feb 2021 by

Women who are hospitalized for myocardial infarction (MI) have a higher risk of long-term negative cardiovascular outcomes compared with men, according to a recent study from Canada.

Heart failure post-MI more frequent in women than men

04 Feb 2021

No excess CV risk with febuxostat vs allopurinol for gout: FAST study

04 Feb 2021 by

Using the urate-lowering drug febuxostat does not come with an excess risk of major cardiovascular (CV) events compared with allopurinol for gout treatment, according to the EMA*-mandated post-authorization safety study, FAST**.

No excess CV risk with febuxostat vs allopurinol for gout: FAST study

04 Feb 2021

Beta blockers plus diuretic tied to lowest SBP in OSA patients

04 Feb 2021

Obstructive sleep apnoea (OSA) patients on antihypertension medication often have poorly controlled blood pressure (BP), reveals a study. Treatment with beta blockers alone or in combination with a diuretic appears to result in the lowest systolic (S)BP in this clinical cohort.

Beta blockers plus diuretic tied to lowest SBP in OSA patients

04 Feb 2021

Cerebral microbleeds predict adverse cardiac, cerebrovascular events in CAD patients

03 Feb 2021

The presence of cerebral microbleeds is associated with major adverse cardiac and cerebrovascular events in patients with coronary artery disease (CAD) on antithrombotic treatment, a study has found.

Cerebral microbleeds predict adverse cardiac, cerebrovascular events in CAD patients

03 Feb 2021

Exenatide once weekly falls short of reducing carotid plaque progression in T2D

03 Feb 2021

The long-acting glucagon-like peptide 1 receptor agonist exenatide once weekly helps improve glycaemic control but does little to modify carotid plaque volume or composition in patients with type 2 diabetes (T2D), according to the results of a trial.

Exenatide once weekly falls short of reducing carotid plaque progression in T2D

03 Feb 2021

Original New Drug Application Approvals by US FDA (16 - 31 January 2021)

02 Feb 2021

New drug applications approved by US FDA as of 16-31 January 2021 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16 - 31 January 2021)

02 Feb 2021

News & Updates

Filter by Specialty:

Specialty:

Higher refined grains intake ups risk of death, major CV events

Higher refined grains intake ups risk of death, major CV events

No need for warfarin after isolated mitral valve repair, says study

No need for warfarin after isolated mitral valve repair, says study

Does gender-affirming hormone therapy affect BP of transgenders?

Does gender-affirming hormone therapy affect BP of transgenders?

Bayer pharma applies breakthrough innovations to manage difficult-to-treat conditions

Bayer pharma applies breakthrough innovations to manage difficult-to-treat conditions

Heart failure post-MI more frequent in women than men

Heart failure post-MI more frequent in women than men

No excess CV risk with febuxostat vs allopurinol for gout: FAST study

No excess CV risk with febuxostat vs allopurinol for gout: FAST study

Beta blockers plus diuretic tied to lowest SBP in OSA patients

Beta blockers plus diuretic tied to lowest SBP in OSA patients

Cerebral microbleeds predict adverse cardiac, cerebrovascular events in CAD patients

Cerebral microbleeds predict adverse cardiac, cerebrovascular events in CAD patients

Exenatide once weekly falls short of reducing carotid plaque progression in T2D

Exenatide once weekly falls short of reducing carotid plaque progression in T2D

Original New Drug Application Approvals by US FDA (16 - 31 January 2021)

Original New Drug Application Approvals by US FDA (16 - 31 January 2021)